Related Experiment Videos
[Familial Mediterranean fever--from gene test to clinical aspects]
1Bernhard-Nocht-Institut, Hamburg.
Abstract:
Familial Mediterranean Fever (FMF) is a genetically defined disease affecting mostly families of jewish, turkish or armenian origin whose ancestors originate from the mediterranean basin. The first officially acknowledged description was given by SIEGAL in 1945 but previous cases were reported since 1908. The main clinical signs which are very varying in intensity and appearance are periodic attacks of fever with peritonitis, pleurisy and arthritis. The classical but not always found complication is amyloidosis with renal failure which is preventable by lifelong colchicine therapy. By using a novel genetest it is now possible to definitely diagnose FMF instead of relying on a diagnosis made merely by exclusion. This will emphasize the use of colchicine and should bring us nearer to the pathophysiology of this interesting disease.
Insights
Familial Mediterranean Fever (FMF) is a genetic disorder primarily affecting Mediterranean populations. A new genetic test enables definitive diagnosis, improving colchicine therapy and understanding of FMF pathophysiology.
Area of Science:
- Genetics
- Immunology
- Internal Medicine
Context:
- Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disorder.
- Historically diagnosed through clinical presentation and exclusion.
- Predominantly affects individuals of Mediterranean, Turkish, Armenian, and Jewish ancestry.
Purpose:
- To highlight the advent of a novel genetic test for FMF diagnosis.
- To emphasize the importance of early and accurate diagnosis for disease management.
- To underscore the role of colchicine therapy in preventing FMF complications like amyloidosis.
Summary:
- FMF is characterized by recurrent episodes of fever, serositis (peritonitis, pleurisy), and arthritis.
- A significant complication is amyloidosis, leading to renal failure, which is preventable with lifelong colchicine.
- A new genetic test allows for definitive FMF diagnosis, moving beyond exclusion criteria.
Impact:
- Facilitates earlier and more precise diagnosis of FMF.
- Reinforces the critical role of lifelong colchicine therapy in managing FMF.
- Aids in advancing the understanding of FMF pathophysiology through genetic insights.